Clinical Efficacy and Quality of Life Assessment of Partial Cystectomy and Plasmakinetic Transurethral Resection of Tumor in Bladder Cancer Patients

Li, Zhijia; Wang, Da-Ya; Zhi-hu, Liu

doi:10.2147/cmar.s346764

Cited by 4 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, all guidelines recommend TURBT as the main method for the treatment of NMIBC, but it still has some deficiencies when put into clinical application. The main manifestations are as follows: (1) The cancer tissue can not be completely removed by the procedure and the postoperative residual rate is high; (2) the operation and efficacy evaluation are not unified and standardized, and they are subject to biases; (3) after electroresection, the postoperative pathological diagnosis is difficult to achieve the standard [ 8 ]. Since the aforementioned problems are inevitable, it is difficult to establish an accurate diagnosis and stage bladder cancer in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

The diagnostic value of fluorescence in situ hybridization in secondary electroresection of bladder cancer

Chen¹,

Shu²,

Liu³

et al. 2023

Bladder

View full text Add to dashboard Cite

OBJECTIVE: To investigate the utility of fluorescence in situ hybridization (FISH) in secondary electroresection of bladder cancer. METHODS: From January 2016 to April 2022, bladder cancer patients who had undergone secondary electroresection in Tongji Hospital and had preoperative urine FISH were recruited, and the positive rate, accuracy, sensitivity, specificity, genetic material changes and predictive power on malignancy degree of FISH in the secondary electroresection of bladder cancer were examined. RESULTS: Twenty-six patients with bladder cancer were included in this study, and 8 were confirmed by secondary electroresection, including 6 cases positive for FISH positive and 2 negative for FISH. Besides, among the subjects, 18 were without tumor recurrence, including 1 case with positive FISH results and 17 with negative FISH results. Tumor recurrence was diagnosed in 85.71% (6/7) of FISH-positive patients in secondary electroresection while only 10.53% (2/19) of FISH-negative patients were found to develop tumor recurrence in the secondary electroresection. The sensitivity of FISH for the detection of bladder cancer before secondary electroresection was 75%, with a specificity of 94.44%, and an accuracy of 88.46%. A 6-month follow-up revealed that 2 of the 8 recurrent patients underwent radical resection of bladder cancer, and the remaining 6 patients had no recurrence, as confirmed by regular bladder perfusion and microscopy. In the 18 non-recurrent patients during secondary electroresection, no recurrence developed.CONCLUSIONS: Urine FISH can achieve a high detection rate and specificity for secondary electroresection of bladder cancer. If a bladder cancer patient who are indicated for secondary electroresection is negative for urine FISH, the recurrence rate after secondary electroresection will be low, and the cystoscopy can be performed before deciding whether to perform secondary electroresection.

show abstract

Section: Discussionmentioning

confidence: 99%

The diagnostic value of fluorescence in situ hybridization in secondary electroresection of bladder cancer

Chen¹,

Shu²,

Liu³

et al. 2023

Bladder

View full text Add to dashboard Cite

show abstract

“…The tumor base and 1-2cm of surrounding mucosa were resected until normal muscle tissue was exposed. A double-lumen indwelling catheter was also placed after the surgery [5].…”

Section: Methodsmentioning

confidence: 99%

Clinical Observation of Transurethral and Suprapubic Laser Therapy for Superficial Bladder Tumors

2023

IJFM

View full text Add to dashboard Cite

Superficial bladder cancer is a highly malignant tumor that may precede invasive bladder cancer. Without timely treatment, there is a high probability of malignancy. Therefore, it is important to take effective measures for timely treatment and prevent disease progression. Based on this, a randomized controlled trial was conducted in this study. Patients were randomly assigned to different treatment groups using a random number table. Different treatment outcomes were observed under two treatment methods, including perioperative indicators, tumor marker levels, quality of life scores, inflammatory factor levels, urinary function, and incidence of postoperative complications. The therapeutic effect of transurethral and suprapubic laser therapy for superficial bladder tumors was analyzed, aiming to provide certain assistance for the treatment of superficial bladder tumors in clinical practice.

show abstract

“…Bladder cancer (BC) is a common malignant tumor of the urinary system, with an incidence ranking the first in this system [1]. It has the highest recurrence rate of any malignancy.…”

Section: Introductionmentioning

confidence: 99%

Molecular and Immunohistochemical assessment of Fibroblast Growth Factor Receptor 3 (FGFR3) gene as a survival time predictor in bladder cancer patients

Mamdouh

Aboushousha

Hammam

et al. 2023

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Mutation signatures contributing to the tumorigenesis of bladder cancer (BC) are complex and heterogeneous, resulting in unpredictable progression, recurrence, and time survival. Clinically, useful prognostic and predictive biomarkers for both disease recurrence and surveillance are therefore needed. Activating fibroblast growth factor receptor 3 (FGFR3) mutations are regarded as early drivers in the molecular pathogenesis of BC. AIM: The aim of the present study is to evaluate the frequency and distribution pattern of FGFR3 mutation in urine sediments of BC patients in relation to its immunohistochemical (IHC) and molecular expression and to determine the prognostic and predictive value of FGFR3 relative to BC. PATIENTS AND METHODS: One hundred and sixty patients with diagnosed BC and 80 healthy controls were recruited. Urine samples were collected from all participants. DNA was extracted and FGFR3 mutations were examined in exons 7, 10, and 15 by polymerase chain reaction. IHC for FGFR3 expression and fluorescence in situ hybridization technique for assessment of gene amplification was also applied in tissue sections. RESULTS: Ninety-eight (61.3%) patients were mutant in exon 7, 82 (51.3%) were mutant in exon 10, while only 14 (8.8%) were mutant in exon 15. Univariate logistic regression analysis revealed that mutations in the three exons of FGFR3 were statistically associated with BC and could be used as predictor and/or prognostic parameters for BC. Receiver operating characteristic analysis showed that the mutation of exons 7 and 10 could be used as diagnostic biomarkers for BC. Our findings confirm that FGFR3 mutations are associated with tumors of low grade and stage. The prevalence of mutations was significantly associated with recurrence and survival time of patients for all exons. Kaplan–Meier analysis revealed a significant association between mutant patients in exon 10 and survival time. Our findings suggest that estimation of FGFR3 expression and gene amplification could serve as a prognostic indicator in the follow-up of BC patients. It could also be utilized for molecular targeted therapy in BC. CONCLUSION: Our data confirmed the feasibility of FGFR3 mutation detection in urine sediment. FGFR3 genetic mutations are independent prognostic factors for tumor recurrence and the genetic alternation of FGFR3 could be used for prediction of survival time of BC patients.

show abstract

Clinical Efficacy and Quality of Life Assessment of Partial Cystectomy and Plasmakinetic Transurethral Resection of Tumor in Bladder Cancer Patients

Cited by 4 publications

References 40 publications

The diagnostic value of fluorescence in situ hybridization in secondary electroresection of bladder cancer

The diagnostic value of fluorescence in situ hybridization in secondary electroresection of bladder cancer

Clinical Observation of Transurethral and Suprapubic Laser Therapy for Superficial Bladder Tumors

Molecular and Immunohistochemical assessment of Fibroblast Growth Factor Receptor 3 (FGFR3) gene as a survival time predictor in bladder cancer patients

Contact Info

Product

Resources

About